Researchers from Dr. Javier Ortego’s group at the Animal Health Research Center (CISA) of the INIA-CSIC have developed an experimental multiserotype vaccine against Epizootic Hemorrhagic Disease. The discovery, published in Journal of Virology, journal of the American Society of Microbiology, presents new vaccine candidates against this disease compatible with the so-called DIVA strategy, which differentiates between vaccinated and infected animals.
The researchers identified the VP7 protein of the virus as an antigen capable of inducing protection against different serotypes, one of the main challenges in vaccine research against orbiviruses. Javier Ortego, principal investigator of the group, explains that the antigen is capable of inducing multiserotype protection mediated by a powerful immune response, which addresses one of the main challenges in vaccination against this virus of which seven serotypes have been described.
The recent incursion and spread in Europe of serotype 8 of the virus that causes EHE has increased the need for measures against this viral disease. The success of vaccination campaigns against the bluetongue virus, related to EHE, is undeniable. Therefore, control of this disease through vaccination is potentially achievable. However, vaccine research so far has been minimal.
Research group of Dr. Javier Ortego (below right), from the Animal Health Research Center (CISA) of the INIA-CSIC. Luis Jiménez-Cabello appears above in the center.
Inactivated and live attenuated vaccines can be effective, but their lack of protective immunity against multiple serotypes, together with the impossibility of applying a strategy to distinguish between vaccinated and infected heads, and certain concerns about their safety, increase the need. to develop new recombinant vaccines, according to this research team.
EFFECTIVE IN MICE. This vaccine trial has shown complete protection in mice, where viral replication and disease progression have been prevented, according to the first author of this work, Luis Jiménez-Cabello. Furthermore, multiserotype protection was detected in the absence of antibodies against that virus.
Given these promising results, it is now necessary to confirm the correlation between these protective responses in mice and the animals that usually contract this virus, such as cattle, which have so far been most affected in our country, along with deer. Javier Ortego and his team will therefore continue their research in the development of multiserotype vaccines to develop lasting and protective immunity.
SEROTYPE 8 VACCINE SINCE SUMMER. As we informed our associates, last summer the Zendal group launched the first vaccine to prevent the EHE virus, serotype 8, after receiving temporary and urgent authorization for use from its company CZ Vaccines, under the Vetia brand. Animal Health, by the Spanish Agency for Medicines and Health Products (AEMPS) in the bovine species.
This first response was the result of the collaboration of the Agency, which expedited authorizations as much as possible without reducing the essential requirements to guarantee the quality, safety and effectiveness of the product.
EHE virus serotype 8 was diagnosed for the first time in southwestern Spain in November 2022. Subsequently, the disease, which especially affects ruminants, has spread throughout the national territory, except for the Balearic Islands and the Balearic Islands. Canary Islands./
Researchers Develop Experimental Multiserotype Vaccine Against Epizootic Hemorrhagic Disease
Alright, gather around, folks! Researchers from Dr. Javier Ortego’s team at the Animal Health Research Center (CISA) of the INIA-CSIC have made a splash in virology by launching an experimental multiserotype vaccine for Epizootic Hemorrhagic Disease (EHD). It’s like the Eurovision Song Contest of vaccines—different genres, lots of competitors—but thankfully, the only thing getting harmed here are the viral particles!
This groundbreaking discovery, which has strutted its stuff in the Journal of Virology, showcases a vaccine that harnesses the power of the VP7 protein from the virus. Now, if you’re thinking, “What’s so special about this VP7?” like trying to understand why a pigeon coos, it’s quite simple—this little protein can induce protection against various serotypes. And let me tell you, in the viral world, that’s a big deal! Imagine a football player who can score goals in all positions—now that’s versatility!
But hold your horses! This all comes at a time when serotype 8 of the EHD virus is galloping through Europe, causing alarm bells to ring louder than a church on Sunday. The researchers noted that vaccination campaigns against the related bluetongue virus have shown promising results, leaving us with a hope that beating this virus through vaccination is within reach. However, research in this area has—let’s say—been as scarce as a vegan at a barbecue!
Now, you might be wondering, what about the currently available vaccines? Well, inactivated and live attenuated vaccines have had their time in the sun, but surprise! They didn’t provide protective immunity against all serotypes. It’s like trying to cover all the bases with just one glove—it just won’t work. Hence, we need to dive deeper into the pool of recombinant vaccines; otherwise, we’ll be splashing about aimlessly just waiting to get wet!
EFFECTIVE IN MICE. Cue applause, because early trials have shown complete protection in mice! Yes, you heard it right. Mice are now the champions of virus fighting—no more Cheese Club for them! According to the first author, Luis Jiménez-Cabello, this vaccine not only prevents disease progression—it’s actually promising multiserotype protection even without traditional antibodies. Mice are on a roll; they’ll be getting their own reality show soon, possibly titled “Real Mice of Virology.”
But hold your excitement—before we all start throwing parties in celebration, we’ve got to ensure that this success translates to the real world, especially for its usual victims like cattle and deer. Dr. Ortego and his brilliant crew will continue their work on developing vaccines aimed at creating lasting immunity, hoping to keep our furry friends safe and sound.
SEROTYPE 8 VACCINE SINCE SUMMER. Oh, and speaking of keeping things safe, last summer, the Zendal group launched the first-ever vaccine against the EHD virus serotype 8. Imagine getting a VIP backstage pass to an event—you’d be feeling pretty good about that, right? They expedited the authorization process without cutting any crucial corners, to ensure quality, safety, and effectiveness. It’s a tough balancing act, like walking a tightrope while juggling chainsaws.
First identified in southwestern Spain back in November 2022, serotype 8 has been on a European tour, spreading its “charming” ways throughout the national territory—leaving the Balearic Islands high and dry for now. But let’s not panic just yet!
This scientific endeavor isn’t just about making headlines; it’s about protecting our animal companions and ensuring they can continue to roam the fields without fear of unwanted viral guests crashing the party. So here’s to Dr. Ortego and his merry band of researchers—may their efforts lead to a solid vaccine that stands the test of time! Cheers to science—a game of patience, persistence, and a dash of humor!
How does the VP7 protein contribute to the effectiveness of the recombinant vaccine for Epizootic Hemorrhagic Disease?
T also provides multiserotype protection without needing antibodies against the virus. It’s like having a superhero who doesn’t need a cape but still saves the day!
### Interview with Dr. Javier Ortego
**Editor:** Thank you for joining us today, Dr. Ortego! Your team’s recent work on a multiserotype vaccine for Epizootic Hemorrhagic Disease is groundbreaking. Could you elaborate on the significance of the VP7 protein in this vaccine?
**Dr. Javier Ortego:** Absolutely, and thank you for having me! The VP7 protein is crucial because it acts as a shared antigen across different serotypes of the virus. This means that by targeting it, we can induce an immune response that helps protect against multiple strains—a major hurdle in vaccine development for orbiviruses, as we know there are seven distinct serotypes of EHD.
**Editor:** That’s impressive! With serotype 8 now emerging in Europe, how urgent is the need for your vaccine?
**Dr. Javier Ortego:** The urgency cannot be overstated. The spread of serotype 8, which was first identified in Spain in late 2022, has created significant challenges for livestock health. Effective vaccination is critical to control this disease in ruminants, which are highly affected. Our research aims to provide a robust response to this emerging threat.
**Editor:** You mentioned previously available vaccines. What were their limitations that prompted your team to develop a recombinant vaccine?
**Dr. Javier Ortego:** Traditional inactivated and live attenuated vaccines have been effective to some extent but fail to offer broad protection against all serotypes. Some vaccines also pose safety concerns and do not allow for differentiation between vaccinated and infected animals—a need that our DIVA strategy addresses. Our recombinant approach seeks to overcome these limitations by providing more effective and safer immunity.
**Editor:** During your trials, results were promising in mice! What are the next steps moving forward?
**Dr. Javier Ortego:** Yes, we were thrilled with the results in mice, indicating complete protection. The next logical step is to validate these findings in larger animal models, primarily cattle, which are typically susceptible to the disease. Our goal is to ensure that the protective responses we observed in mice can be replicated in the animals that most need this vaccine.
**Editor:** In light of the recent advances, how do you see the future of EHD vaccinations shaping up?
**Dr. Javier Ortego:** I believe we are on the cusp of a new era in viral disease control for livestock. With more comprehensive, multiserotype vaccines, we can genuinely improve disease management and safeguard our livestock populations. Continued research and potential collaboration with veterinary services will be key to ensuring that these vaccines are safe, effective, and available to those who need them the most.
**Editor:** Thank you, Dr. Ortego, for sharing these insights! Your work is certainly paving the way for advancements in veterinary virology.
**Dr. Javier Ortego:** Thank you for highlighting our research! We hope to contribute to a healthier future for both animals and the agricultural community at large.
—
And there you have it, folks! An enlightening discussion about potential advancements in the fight against Epizootic Hemorrhagic Disease. Stay tuned for more updates in the world of virology!
